دورية أكاديمية
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.
| العنوان: | The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena. |
|---|---|
| المؤلفون: | van den Bergh JP; Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands. joop.vandenbergh@maastrichtuniversity.nl.; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. joop.vandenbergh@maastrichtuniversity.nl., Geusens P; Department of Internal Medicine, Subdivision Rheumatology, Maastricht University Medical Center, Maastricht, the Netherlands.; Department of Medicine and Life Science, Hasselt University, Hasselt, Belgium., Appelman-Dijkstra NM; Department of Internal Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands., van den Broek HJG; Osteoporose Vereniging, Bilthoven, the Netherlands., Elders PJM; Department of General Practice, Amsterdam Public Health Institute, Amsterdam UMC, Amsterdam, the Netherlands., de Klerk G; Department of Surgery, ADRZ, Goes, the Netherlands., van Oostwaard M; Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands.; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands., Willems HC; Department of Internal Medicine and Geriatrics, Amsterdam University Medical Center, Amsterdam, the Netherlands., Zillikens MC; Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands., Lems WF; Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, the Netherlands. |
| المصدر: | Archives of osteoporosis [Arch Osteoporos] 2024 Apr 02; Vol. 19 (1), pp. 23. Date of Electronic Publication: 2024 Apr 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: England NLM ID: 101318988 Publication Model: Electronic Cited Medium: Internet ISSN: 1862-3514 (Electronic) NLM ISO Abbreviation: Arch Osteoporos Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Springer, [2006]- |
| مواضيع طبية MeSH: | Osteoporosis*/drug therapy , Hip Fractures*/prevention & control, Humans ; Teriparatide ; Zoledronic Acid ; Ethnicity |
| مستخلص: | Background: In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions. Methods: A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient's organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline. Results: Novel recommendations in our guideline are as follows: - In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA. - Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk; - Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA); - Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk; - A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment. Conclusion: In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 "relatively new statements" that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation. (© 2024. The Author(s).) |
| References: | Arthritis Rheum. 2009 Nov;60(11):3346-55. (PMID: 19877063) J Bone Miner Res. 2000 Apr;15(4):721-39. (PMID: 10780864) Am J Clin Nutr. 2007 Apr;85(4):1068-74. (PMID: 17413107) Arch Osteoporos. 2016;11:12. (PMID: 26906974) Best Pract Res Clin Rheumatol. 2022 Sep;36(3):101759. (PMID: 35729036) Osteoporos Int. 2016 Apr;27(4):1389-1399. (PMID: 26556742) Lancet Healthy Longev. 2023 Aug;4(8):e386-e398. (PMID: 37442154) Aging Clin Exp Res. 2021 Jan;33(1):19-24. (PMID: 32857334) Ann Rheum Dis. 2017 May;76(5):802-810. (PMID: 28007756) J Clin Endocrinol Metab. 2011 May;96(5):1360-7. (PMID: 21411547) N Engl J Med. 2007 Nov 1;357(18):1799-809. (PMID: 17878149) J Clin Endocrinol Metab. 2019 May 1;104(5):1623-1630. (PMID: 30907957) Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. (PMID: 29631782) JAMA Intern Med. 2014 Jul;174(7):1126-34. (PMID: 24798675) Bone. 2004 Jan;34(1):195-202. (PMID: 14751578) BMJ. 2016 Jun 28;353:i2016. (PMID: 27353417) J Bone Miner Res. 2019 Mar;34(3):409-418. (PMID: 30645770) Osteoporos Int. 2020 Nov;31(11):2269-2270. (PMID: 32965511) Lancet. 2006 Nov 11;368(9548):1648. (PMID: 17098078) BMJ Open. 2022 Jul 27;12(7):e058983. (PMID: 35896286) Lancet. 2009 Apr 11;373(9671):1253-63. (PMID: 19362675) J Bone Miner Res. 1993 Sep;8(9):1137-48. (PMID: 8237484) J Bone Miner Res. 2021 Sep;36(9):1680-1693. (PMID: 34033146) Osteoporos Int. 2020 Jan;31(1):1-12. (PMID: 31720707) Am J Med. 2016 Feb;129(2):221.e1-10. (PMID: 26524708) Lancet. 2018 Jan 20;391(10117):230-240. (PMID: 29129436) JAMA Intern Med. 2016 Feb;176(2):175-83. (PMID: 26747333) JAMA. 2006 Dec 27;296(24):2927-38. (PMID: 17190893) J Bone Miner Res. 2020 Jun;35(6):1014-1021. (PMID: 31999376) Osteoporos Int. 2011 May;22(5):1537-46. (PMID: 20838773) Osteoporos Int. 2020 Jul;31(7):1193-1204. (PMID: 32266437) J Am Coll Nutr. 2004 Dec;23(6):701S-3S. (PMID: 15637218) J Bone Miner Res. 1992 Feb;7(2):221-7. (PMID: 1570766) Ann Rheum Dis. 2007 Jan;66(1):2-4. (PMID: 17178757) Front Pharmacol. 2019 Aug 09;10:882. (PMID: 31447677) J Bone Miner Res. 2012 Oct;27(10):2039-46. (PMID: 22836222) Osteoporos Int. 2021 Mar;32(3):399-411. (PMID: 33475820) Aging Clin Exp Res. 2019 Jan;31(1):15-17. (PMID: 30612282) BMJ. 2016 Jun 30;353:i2089. (PMID: 27365494) Osteoporos Int. 2007 Jun;18(6):761-70. (PMID: 17245546) Osteoporos Int. 2015 Jan;26(1):419-20. (PMID: 25257932) Lancet. 2003 Oct 11;362(9391):1225-30. (PMID: 14568747) Osteoporos Int. 2020 Nov;31(11):2093-2102. (PMID: 32613409) Bone Joint J. 2015 Mar;97-B(3):372-82. (PMID: 25737522) J Clin Endocrinol Metab. 2014 Dec;99(12):4546-54. (PMID: 25215556) N Engl J Med. 2017 Oct 12;377(15):1417-1427. (PMID: 28892457) Arch Osteoporos. 2023 Jul 10;18(1):93. (PMID: 37428295) J Bone Miner Res. 2005 Jul;20(7):1216-22. (PMID: 15940375) JAMA. 2010 May 12;303(18):1815-22. (PMID: 20460620) Drugs. 2019 Jul;79(10):1065-1087. (PMID: 31201710) |
| فهرسة مساهمة: | Keywords: Fracture prevention; Multidisciplinary guideline; Osteoporosis |
| المشرفين على المادة: | 10T9CSU89I (Teriparatide) 6XC1PAD3KF (Zoledronic Acid) |
| تواريخ الأحداث: | Date Created: 20240402 Date Completed: 20240403 Latest Revision: 20240405 |
| رمز التحديث: | 20240405 |
| مُعرف محوري في PubMed: | PMC10987374 |
| DOI: | 10.1007/s11657-024-01378-3 |
| PMID: | 38564062 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!